IDEAYA Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 124
- Market Cap
- $3.3B
- Website
- http://www.ideayabio.com
- Introduction
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
FDA Clears IND for IDEAYA's Novel DLL3-Targeting Antibody Drug Conjugate IDE849 for Solid Tumors
IDEAYA Biosciences has received FDA clearance for a Phase 1 clinical trial of IDE849, a potential first-in-class DLL3-targeting Topo-I-payload antibody drug conjugate for solid tumors including small cell lung cancer and neuroendocrine tumors.
FDA Grants Breakthrough Therapy Designation to IDEAYA's Darovasertib for Neoadjuvant Uveal Melanoma
The FDA has granted Breakthrough Therapy designation to darovasertib, a first-in-class protein kinase C inhibitor, for neoadjuvant treatment of primary uveal melanoma patients facing eye removal.
IDEAYA's WRN Inhibitor IDE275 Shows Promise for MSI-H Cancers, Featured in AACR 2025 Oral Presentation
IDEAYA Biosciences and GSK will present promising data on IDE275 (GSK959), a potential best-in-class Werner Helicase inhibitor for MSI-H solid tumors, at AACR 2025's New Drugs on the Horizon series.
IDEAYA and ATTMOS Partner to Pioneer AI-Driven Drug Discovery for Undruggable Cancer Targets
IDEAYA Biosciences has formed a strategic collaboration with ATTMOS to develop a physics-based computational platform for discovering small molecule drugs targeting previously undruggable oncology targets.
Amgen and Ideaya Terminate Cancer Combination Trial for PRMT5 and MAT2A Inhibitors
Amgen and Ideaya Biosciences have mutually agreed to discontinue their clinical collaboration testing the combination of AMG 193 and IDE397 for solid tumors.
IDEAYA Biosciences Reports Strong Pipeline Progress and $1.1B Cash Position for 2024
IDEAYA Biosciences advances multiple oncology programs, with over 230 patients enrolled in potential registration-enabling trial for darovasertib in metastatic uveal melanoma, targeting key readouts by end of 2025.
IDEAYA and Amgen Discontinue IDE397/AMG 193 Combination Study Despite Promising Preclinical Data
IDEAYA Biosciences and Amgen have mutually agreed to terminate their clinical combination study of IDE397 and AMG 193, leading Oppenheimer to reduce IDEAYA's price target to $40 from $53.
IDEAYA Biosciences Announces Strategic Updates and 2025 Corporate Guidance
IDEAYA Biosciences has a strong financial position with $1.2 billion in cash, expected to fund operations into at least 2028.
IDEAYA Biosciences Licenses DLL3-Targeting ADC from Hengrui Pharma in $1B Deal
IDEAYA Biosciences has secured an exclusive license from Hengrui Pharma for SHR-4849, a DLL3-targeting antibody-drug conjugate (ADC), outside of Greater China.
IDEAYA's Darovasertib and Crizotinib Combination Advances in Uveal Melanoma Trial
IDEAYA Biosciences' combination therapy of darovasertib and crizotinib receives IDMC recommendation to advance to Part 2b of Phase 2/3 trial.